Full Press Release Details
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.
44thAnnual J.P. Morgan Healthcare ConferenceFormat: Presentation and one-on-one investor meetingsDate: January 15, 2026Presentation Time 8:15 a.m. PST/11:15am ESTWebcast Link:Click Here
About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visitcorbuspharma.com. Connect with us onX,LinkedInandFacebook.
INVESTOR CONTACTS:Sean MoranChief Financial OfficerCorbus Pharmaceuticalssmoran@corbuspharma.com
Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com